

Naudotos literatūros sąrašas:

1. Alton, E. W., J. M. Beekman, A. C. Boyd, J. Brand, M. S. Carlon, M. M. Connolly, M. Chan, S. Conlon, H. E. Davidson, J. C. Davies, L. A. Davies, J. F. Dekkers, A. Doherty, S. Gea-Sorli, D. R. Gill, U. Griesenbach, M. Hasegawa, T. E. Higgins, T. Hironaka, L. Hyndman, G. McLachlan, M. Inoue, S. C. Hyde, J. A. Innes, T. M. Maher, C. Moran, C. Meng, M. C. Paul-Smith, I. A. Pringle, K. M. Pytel, A. Rodriguez-Martinez, A. C. Schmidt, B. J. Stevenson, S. G. Sumner-Jones, R. Toshner, S. Tsugumine, M. W. Wasowicz and J. Zhu (2017). Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. *Thorax*. 72: 137- 147.
2. Biffi, A., C. C. Bartholomae, D. Cesana, N. Cartier, P. Aubourg, M. Ranzani, M. Cesani, F. Benedicenti, T. Plati, E. Rubagotti, S. Merella, A. Capotondo, J. Sgualdino, G. Zanetti, C. von Kalle, M. Schmidt, L. Naldini and E. Montini (2011). Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. *Blood*. 117: 5332-9.
3. Brentjens, R. J., I. Riviere, J. H. Park, M. L. Davila, X. Wang, J. Stefanski, C. Taylor, R. Yeh, S. Bartido, O. Borquez-Ojeda, M. Olszewska, Y. Bernal, H. Pegram, M. Przybylowski, D. Hollyman, Y. Usachenko, D. Pirraglia, J. Hosey, E. Santos, E. Halton, P. Maslak, D. Scheinberg, J. Jurcic, M. Heaney, G. Heller, M. Frattini and M. Sadelain (2011). Safety and persistence of adoptively transferred autologous CD19- targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. *Blood*. 118: 4817- 28.
4. Carmo, M., A. Alves, A. F. Rodrigues, A. S. Coroadinha, M. J. Carrondo, P. M. Alves and P. E. Cruz (2009). Stabilization of gammaretroviral and lentiviral vectors: from production to gene transfer. *J Gene Med*. 11: 670-8.
5. Chmielewski, M., A. A. Hombach and H. Abken (2013). Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. *Front Immunol*. 4: 371.
6. David, R. M. and A. T. Doherty (2017). Viral Vectors: The Road to Reducing Genotoxicity. *Toxicological Sciences*. 155: 315-325.
7. Davila, M. L., I. Riviere, X. Wang, S. Bartido, J. Park, K. Curran, S. S. Chung, J. Stefanski, O. Borquez- Ojeda, M. Olszewska, J. Qu, T. Wasielewska, Q. He, M. Fink, H. Shinglot, M. Youssif, M. Satter, Y. Wang, J. Hosey, H. Quintanilla, E. Halton, Y. Bernal, D. C. Bouhassira, M. E. Arcila, M. Gonen, G. J. Roboz, P. Maslak, D. Douer, M. G. Frattini, S. Giralt, M. Sadelain and R. Brentjens (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. *Sci Transl Med*. 6: 224ra25
8. Lewinski, M. K., M. Yamashita, M. Emerman, A. Ciuffi, H. Marshall, G. Crawford, F. Collins, P. Shinn, J. Leipzig, S. Hannenhalli, C. C. Berry, J. R. Ecker and F. D. Bushman (2006). Retroviral DNA integration: viral and cellular determinants of target-site selection. *PLoS Pathog*. 2: e60.
9. Maude, S. L., N. Frey, P. A. Shaw, R. Aplenc, D. M. Barrett, N. J. Bunin, A. Chew, V. E. Gonzalez, Z. Zheng, S. F. Lacey, Y. D. Mahnke, J. J. Melenhorst, S. R. Rheingold, A. Shen, D. T. Teachey, B. L. Levine, C. H. June, D. L. Porter and S. A. Grupp (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. *N Engl J Med*. 371: 1507-17.
10. Montini, E., D. Cesana, M. Schmidt, F. Sanvito, C. C. Bartholomae, M. Ranzani, F. Benedicenti, L. S. Sergi, A. Ambrosi, M. Ponzoni, C. Doglioni, C. Di Serio, C. von Kalle and L. Naldini (2009). The genotoxic potential of retroviral vectors is strongly

- modulated by vector design and integration site selection in a mouse model of HSC gene therapy. *J Clin Invest.* 119: 964-75.
11. Park, J. H., M. B. Geyer and R. J. Brentjens (2016). CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. *Blood.* 127: 3312-20.
 12. Schambach, A., D. Zychlinski, B. Ehrnstroem and C. Baum (2013). Biosafety features of lentiviral vectors. *Hum Gene Ther.* 24: 132-42.
 13. Schneider, D., Y. Xiong, D. Wu, V. Nlle, S. Schmitz, W. Haso, A. Kaiser, B. Dropulic and R. J. Orentas (2017). A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. *J Immunother Cancer.* 5: 42.
 14. van der Stegen, S. J. C., M. Hamieh and M. Sadelain (2015). The pharmacology of second-generation chimeric antigen receptors. *Nat Rev Drug Discov.* Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. 14: 499-509.
 15. Zhu, F., N. Shah, H. Xu, D. Schneider, R. Orentas, B. Dropulic, P. Hari and C. A. Keever-Taylor (2018). Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. *Cytotherapy.* 20: 394-406.
 16. Brudno, J. N., R. P. Somerville, V. Shi, J. J. Rose, D. C. Halverson, D. H. Fowler, J. C. Gea-Banacloche, S. Z. Pavletic, D. D. Hickstein, T. L. Lu, S. A. Feldman, A. T. Iwamoto, R. Kurlander, I. Maric, A. Goy, B. G. Hansen, J. S. Wilder, B. Blacklock-Schuver, F. T. Hakim, S. A. Rosenberg, R. E. Gress and J. N. Kochenderfer (2016). Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. *J Clin Oncol.* 34: 1112-21.
 17. Turtle, C. J., L. A. Hanafi, C. Berger, T. A. Gooley, S. Cherian, M. Hudecek, D. Sommermeyer, K. Melville, B. Pender, T. M. Budiarto, E. Robinson, N. N. Steevens, C. Chaney, L. Soma, X. Chen, C. Yeung, B. Wood, D. Li, J. Cao, S. Heimfeld, M. C. Jensen, S. R. Riddell and D. G. Maloney (2016). CD19 CAR-T cells of defined CD4⁺:CD8⁺ composition in adult B cell ALL patients. *J Clin Invest.* 126: 2123-38.
 18. Turtle, C. J., K. A. Hay, L. A. Hanafi, D. Li, S. Cherian, X. Chen, B. Wood, A. Lozanski, J. C. Byrd, S. Heimfeld, S. R. Riddell and D. G. Maloney (2017). Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. *J Clin Oncol.* Jco2017728519.